Navigation Links
Medicago initiates work on Swine Flu strain
Date:4/28/2009

p>

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release


'/>"/>
SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
4. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
5. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
6. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
7. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
8. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
9. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
10. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis
11. Memory Pharmaceuticals Initiates Phase 2a Trial of MEM 3454 in Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... PROVO, Utah , July 10, 2014 ... genome annotation and interpretation, today announced an ... sequencing (NGS) analytics for Lineagen,s NextStep Dx ... evaluation of neurodevelopmental and neurological disorders, currently ... chromosomal microarray (CMA) testing service used by ...
(Date:7/10/2014)... Adelaide research may help in the fight against terrorism ... tiny quantities of explosives with the use of light ... Sensors and Actuators B: Chemical , the researchers ... explosives in concentrations as low as 6.3 ppm (parts ... a few minutes. , "Traditionally explosives detection has involved ...
(Date:7/10/2014)... quantum Hall effect in bilayer graphene and shown that ... an electric field. , The fractional quantum Hall ... sheets are exposed to large magnetic fields, is a ... electrons behave as a single system. However, while the ... details of this collective behavior remain not well understood, ...
(Date:7/10/2014)... researchers at the University of Illinois at Urbana-Champaign ... the interplay of spin and heat at the ... spintronic devices for data storage and information processing. ... as spin-angular momentum. In a typical charge current, ... spin current," explained David Cahill, a professor of ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Detecting trace amounts of explosives with light 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3University of Illinois study advances limits for ultrafast nano-devices 2
... 27 A copy of the Company,s December 31, 2008 ... may be obtained without charge at our website address, ... P. O. Box 14508, St. Louis, Missouri 63178. About ... Science and High Technology ...
... - Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) today reported ... 30, 2008. All dollar amounts referenced herein are in Canadian ... cash and cash equivalents totaled $8.6 million, compared with $23.5 ... 31, 2008. As of January 31, 2009, our cash balance ...
... option for millions of Americans with debilitating lung ... (NYSE: AZN ) today announced that ... approved SYMBICORT (budesonide/formoterol fumarate dihydrate) 160/4.5 mcg for ... in patients with chronic obstructive pulmonary disease (COPD), ...
Cached Biology Technology:Vasogen Announces 2008 Year-End Results 2Vasogen Announces 2008 Year-End Results 3Vasogen Announces 2008 Year-End Results 4Vasogen Announces 2008 Year-End Results 5Vasogen Announces 2008 Year-End Results 6Vasogen Announces 2008 Year-End Results 7Vasogen Announces 2008 Year-End Results 8Vasogen Announces 2008 Year-End Results 9Vasogen Announces 2008 Year-End Results 10Vasogen Announces 2008 Year-End Results 11FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 2FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 3FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 4FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 5FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD) 6
(Date:7/11/2014)... marginal division of the striatum is also involved ... degree of substance P in the striatal marginal ... and his team, College of Biophotonics, South China ... substance P receptor, neurokinin 1 was highly expressed ... normal rats. Unilateral or bilateral injection of an ...
(Date:7/11/2014)... that let nerve cells send out electrical signals, Johns ... tactic that may offer a new way to protect ... responsible way. , Their findingthat naturally occurring insect ... for a closely related onesuggests that insecticides can be ... like bees. A summary of the research, led by ...
(Date:7/10/2014)... YORK , June 27, 2014  Pomerantz ... Provectus Biopharmaceuticals, Inc. ("Provectus" or the "Company")(NYSE-MKT: PVCT) ... filed in United States District Court, Middle District ... is on behalf of a class consisting of ... acquired Provectus securities between December 17, 2013 and ...
Breaking Biology News(10 mins):Potent spider toxin 'electrocutes' German, not American, cockroaches 2Potent spider toxin 'electrocutes' German, not American, cockroaches 3SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3
... La Jolla, CA, October 28, 2010 For Immediate ... Research Institute and the Scripps Translational Science Institute has ... collections of rare genetic variations that reveal whether people ... cancer. In our modern genetic age, the ...
... Ancient gardens are the stuff of legend, from the Garden ... at Tel Aviv University, in collaboration with Heidelberg University in ... of Ramat Rachel near Jerusalem, and are leading the first ... the pre-Hellenistic Levant. According to Prof. Oded ...
... clung to life in the branches of trees hemming ... more than 230,000 coastal residents in Indonesia, India, Thailand ... land change scientist Chandra Giri from the U.S. Geological ... unique trees which make up valuable forest ecosystems ...
Cached Biology News:Scientists describe new approach for identifying genetic markers for common diseases 2Scientists describe new approach for identifying genetic markers for common diseases 3Paradise lost -- and found 2Root of the matter: A new map shows life-saving forests' scarcity defies past estimates 2Root of the matter: A new map shows life-saving forests' scarcity defies past estimates 3Root of the matter: A new map shows life-saving forests' scarcity defies past estimates 4Root of the matter: A new map shows life-saving forests' scarcity defies past estimates 5
Bovine Renal Artery Smooth Muscle Cells (BRASMC) (>500,000 cells)...
Sulfadimethoxine (CH-2027)...
Bovine Endometrium Epithelial Cells (BEnEpC) (>500,000 cells)...
... known as smooth muscle cell specific protein, is ... various tissues such as intestine, lung and uterus. ... calponin. SM22 alpha expression has been reported in ... vascular and visceral forms. It is also reported ...
Biology Products: